title: Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
abstract: In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. We analyzed seven prospectively designed placebo-controlled trials involving 3,080 patients, 1,689 of whom received the study drug in doses ranging from 1 mg to 20 mg daily for a total of 1,282 patient-years of exposure. The most common side effects seen in treated patients were dizziness (10.7%), asthenia (7.5%), and peripheral edema (4.0%). These side effects were generally reported as mild and improved after cessation of therapy. The incidence of withdrawal from the study due to side effects was 14.5% in the treatment arm versus 11.4% in the placebo control arm. Also noted was a statistically significant decreased risk of urinary tract infection and myocardial infarction in the terazosin-treated group. This updated report confirms that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.
authors.affiliation: Department of Urology, St. Lukes-Roosevelt Hospital Center, New York, NY 10019, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: McKiernan
authors.forename: F C
authors.initials: FC
authors.lastname: Lowe
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D004244:Dizziness / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000209:etiology; D008297:Male; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin